$450 Million
Joint Bookrunner
Common Stock Financing
September 2023
$100 Million
Joint Bookrunner
Follow-On
September 2023
$350 Million
Joint Bookrunner
Follow-On
September 2023
$175 Million
Joint Bookrunner
Follow-On
September 2023
$70 Million
Joint Bookrunner
Follow-On
August 2023
Up to $213 Million
Financial Advisor
Sale to Regeneron
Pending
Up to $291 Million
Financial Advisor
Acquisition of Spectrum Pharmaceuticals
July 2023
$80 Million
Joint Bookrunner
Initial Public Offering
July 2023
$212 Million
Lead Placement Agent
Private Placement
July 2023
UNDISCLOSED
Exclusive Financial Advisor
Merger with Neurogene
Pending
UNDISCLOSED
Exclusive Financial Advisor
Sale to MediPacific, Inc.
Pending
$125 Million
Joint Bookrunner
Follow-On
July 2023